Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 2, 2002 - Issue 6
Submit an article Journal homepage
29
Views
1
CrossRef citations to date
0
Altmetric
Review

Therapeutic drug monitoring: is it cost-effective?

Gerald E Schumacherand National Education and Research Center for Outcomes Assessment, School of Pharmacy, Bouvé College of Health Sciences, Northeastern University, Boston, MA, USA. [email protected]
&
Judith T Barr National Education and Research Center for Outcomes Assessment, School of Pharmacy, Bouvé College of Health Sciences, Northeastern University, Boston, MA, USA. [email protected]
Pages 619-624 | Published online: 09 Jan 2014

References

  • Barr JT, Schumacher GE. Outcomes assessment in therapeutic drug monitoring. In: Therapeutic Drug Monitoring. Schumacher GE (Ed.), Appleton & Lange, Norwalk, CT, USA, 191–236 (1995).
  • •Most complete tabulation, discussion and evaluation of economic and noneconomic considerations published in TDM and is comprehensive up to 1994.
  • Schumacher GE, Barr JT. Economic and outcome issues for therapeutic drug monitoring in medicine. Ther. Drug Montt. 20, 539–542 (1998).
  • Ensom MIIII, Davis GA, Cropp CD, Ensom RJ. Clinical pharmacokinetics in the 21st century: does the evidence support definitive outcomes? Gun. Pharmacokinet. 34, 265–279 (1998).
  • •Thorough summary of TDM outcomes in tabular form.
  • Pied LD, Horn JR, McKenna DA. Therapeutic drug monitoring reduces toxic drug reactions: a meta-analysis. Ther. Drug Montt. 15, 608–610 (1993).
  • Schumacher GE, Barr JT. Total testing process applied to therapeutic drug monitoring impact on patients' outcomes and economics. Gin. Chem. 44, 370–374 (1998).
  • Gentry CA, Rodvold KA. How important is therapeutic drug monitoring in the prediction and avoidance of adverse reactions? Drug Safety 12, 359–363 (1995).
  • Vozeh S. Cost-effectiveness of therapeutic drug monitoring. Clin. Pharmacokinet. 13, 131–140 (1987).
  • Gardner DM, Hardy BG. Cost-effectiveness of therapeutic drug monitoring. Can. J. Harp. Phann 43, 7–12 (1990).
  • Destache CJ. Use of therapeutic drug monitoring in pharmacoeconomics. Ther. Drug Montt. 15, 608–610 (1993).
  • Destache CJ. Economic aspects of pharmacokinetic services. PharmacoEconomics 3, 433–436 (1993).
  • Slaughter PL, Cappelletty DM. Economic impact of aminoglycoside toxicity and its prevention through therapeutic drug monitoring. PharmacoEconomics 14, 385–394 (1998).
  • Schumacher GE, Barr JT. Therapeutic drug monitoring — do the improved outcomes justify the costs? Gin. Pharmacokinet. 40, 405–409 (2001).
  • Einarson T, Segal H, Mann J. Serum drug utilization: a literature analysis. Can. J. Hosp. Pharm. 42, 63–68 (1989).
  • Schloemer JH, Zagozen JJ. Cost analysis of an aminoglyooside pharmacokinetic dosing service. Am. J Hosp. Pharm 41, 2347–2351 (1984).
  • Bootman JL, Wertheimer AI, Zaske D eta]. Individualizing gentamicin dosage regimens in burn patients with Gram-negative septicemia: a cost-benefit analysis. J. Pharm. Sc]. 68, 268–272 (1979).
  • •First published economic evaluation of TDM.
  • Kimmelblatt BJ, Bradbury K, Chodoff L et al Cost-benefit analysis of an aminoglycoside monitoring service. Am. J. Hosp. Pharm. 43, 1205–1209 (1986).
  • Crist KD, Nahata MC, Ety J. Positive impact of a therapeutic drug-monitoring program on total aminoglycoside dose and cost of hospitalization. Ther. Drug Montt. 9, 306–310 (1987).
  • Destache CJ, Meyer SK, Bittner MJ, Hermann KG. Impact of a clinical pharmacokinetic service on patients treated with aminoglycosides: a cost-benefit analysis. Ther. Drug Montt. 12, 419–426 (1990).
  • Destache CJ, Meyer SK, Rowley KM. Does accepting pharmacokinetic recommendations impact hospitalization? A cost-benefit analysis. Ther. Drug Montt. 12, 427–433 (1990).
  • Burton M, Ash C, Hifi D eta]. A controlled trial of the cost-benefit of a computerized bayesian aminoglycoside administration. Clin. Phannacol Ther 495, 685–694 (1991).
  • Pinilla J, Shafran S, Conly J. A utilization and cost-benefit analysis of an aminoglycoside kinetics monitoring service. Clin. Invest. Med. 15, 8–17 (1992).
  • Binder L, Schiel X, Binder C etal. Clinical outcome and economic impact of aminoglycoside peak concentrations in febrile immunocompromised patients hematologic malignancies. Clin. Chem 44, 408–414 (1998).
  • Van Lent-Evers NAEM, Mathot RAA, Geus WP etal. Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis. Ther Drug Montt. 21, 63–73 (1999).
  • Fernandez de Gatta M, Calvo V, Hernandez JM etal. Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies. Gin. Pharmacol Ther. 60, 332–340 (1996).
  • Pane CT, Dalvi SS, Gogtay NJ etal. A pharmacoeconomic analysis of the impact of therapeutic drug monitoring in adult patients with generalized tonic—donic epilepsy. Brj Clin. Phannacol 52, 193–195 (2001).
  • Murphy JE, Slack MK, Campbell S. National survey of hospital-based pharmacokinetic services. Am. J. Health-Syst. Pharm. 53, 2840–2847 (1996).
  • Bertino JS, Rodvold KA, Destache CJ. Cost considerations in therapeutic drug monitoring of aminoglycosides. Clin. Pharmacokinet. 26, 71–81 (1994).
  • Van Heeswijk RPG. Critical issues in therapeutic drug monitoring of antiretroviral drugs. Ther. Drug Montt. 24, 323–331 (2002).
  • Hon YY, Evans WE. Making TDM work to optimize cancer chemotherapy: a multidisciplinary team approach. Clin. Chem 44, 388–400 (1998).
  • Tsunoda SM, Aweeka FT. The use of therapeutic drug monitoring to optimise immunosuppressive therapy. Clin. Pharmacokinet. 30, 107–140 (1996).
  • Potter JM. Pharmacoeconomics of therapeutic drug monitoring in transplantation. Ther. Drug Montt. 22, 36–39 (2000).
  • Kahan BD, Keown P, Levy GA, Johnston A. Therapeutic drug monitoring of immunosuppresant drugs in clinical practice. Gin. Ther. 24, 330–350 (2002).
  • Walson PD. Therapeutic drug monitoring in special populations. Clin. Chem 44, 415–419 (1998).
  • Soldin OP, Soldin SJ. Review: Therapeutic drug monitoring in pediatrics. Ther. Drug Montt. 24, 1–8 (2002).
  • Brodie MJ, McIntosh ME, Hallworth M. Therapeutic drug monitoring — the need for audit? Scott. Med. 30, 75–82 (1985).
  • Spector R, Park GD, Johnson GF, Vesell ES. Therapeutic drug monitoring. Gin. Pharmacol Ther. 43, 345–353 (1988).
  • McInnes GT. The value of therapeutic drug monitoring to the practising physician — an hypothesis in need of testing. Br. J. Clin. Pharmacol 27, 281–284 (1989).
  • El Desoky E, Klotz U. Value, limitations and clinical impact of therapeutic drug monitoring in adults. Drug Invest. 6, 127–136 (1993).
  • Tonkin AL, Bochner F. Therapeutic drug monitoring and patient outcome: a review of the issues. Clin. Pharmacokinet. 27, 169–174 (1994).
  • Warner A. Setting standards of practice in therapeutic drug monitoring and clinical toxicology: a North American view. Ther. Drug Montt. 22, 93–97 (2000).
  • Gold MR. (Ed.). Cost-effectiveness in Health and Medicine. Oxford University Press, New York, NY, USA (1996).
  • Ensom MHH, Chang TKH, Patel P Pharmacogenetics — the therapeutic drug monitoring of the future? Clin. Pharmacokinet. 40, 783–802 (2001).
  • Campbell M. Community-based therapeutic drug monitoring — useful development or unnecessary distraction? Pharmacokinet. 28, 271–274 (1995).

Websites

  • Piscitelli SC. The limited value of therapeutic drug monitoring in HIV infection. www.medscape.comiviewartidei 408260 (accessed May 1, 2002).
  • Harrington M. Therapeutic drug monitoring (TDM): Ready for prime time? www.aidsinfonyc.orgitagibiltdm3.html (accessed April 26, 2002).
  • Fletcher CV. Clinical significance of antiretroviral drug levels. www.medscape.com/viewartide/418624 (accessed April 30, 2002).
  • Becker SL, Hoetelmans RION. Exploiting pharmacokinetics to optimize antiretroviral therapy. www.medscape.com/viewprogram/ 703 (accessed April 30, 2002).
  • Becker SL, Luber AD. Therapeutic drug monitoring for antiretrovirals: Uses and misuses in clinical practice. www.medscape.com/viewartide/424121 (accessed April 26, 2002).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.